TNF and Opportunistic infection: Although it has been suggested that the risk of opportunistic infections is increased with anti-TNF-α therapy, recent studies have shown that the risks have varied, while vedolizumab, for example, has not been associated with major infectious complications because of its primary gut selectivity [10].